Background: Bronchial Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. The chronic inflammation causes an associated increase in airway hyper responsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning. These episodes are usually associated with widespread but variable airflow obstruction that is often reversible either spontaneously or with treatment. It is a heterogeneous pulmonary disorder characterized by recurrent episodes of cough, breathlessness, and wheezing, which may resolve spontaneously or after the use of bronchodilator medication. The global prevalence of asthma is anticipated to be approximately 4.5 per cent. There are about 334 million patients with asthma affecting all age groups across the world5. The prevalence of asthma has increased over time and an additional 100 million people worldwide are expected to develop asthma by the year 2025. Methods: The present prospective study has been done in Vizianagaram population in Maharajah`s institute of medical sciences to compare the efficacy and safety between combination therapy of salmeterol with fluticasone and formoterol with budesonide in moderate persistent asthma. Results & Conclusion: Formoterol budesonide combination is better in comparison to the salmeterol fluticasone combination considering the lesser no of exacerbations and bronchodilator effect, both salmeterol and formoterol being long-acting bronchodilators.

Background: Bronchial Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. The chronic inflammation causes an associated increase in airway hyper responsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning. These episodes are usually associated with widespread but variable airflow obstruction that is often reversible either spontaneously or with treatment. It is a heterogeneous pulmonary disorder characterized by recurrent episodes of cough, breathlessness, and wheezing, which may resolve spontaneously or after the use of bronchodilator medication. The global prevalence of asthma is anticipated to be approximately 4.5 per cent. There are about 334 million patients with asthma affecting all age groups across the world5. The prevalence of asthma has increased over time and an additional 100 million people worldwide are expected to develop asthma by the year 2025. Methods: The present prospective study has been done in Vizianagaram population in Maharajah`s institute of medical sciences to compare the efficacy and safety between combination therapy of salmeterol with fluticasone and formoterol with budesonide in moderate persistent asthma. Results & Conclusion: Formoterol budesonide combination is better in comparison to the salmeterol fluticasone combination considering the lesser no of exacerbations and bronchodilator effect, both salmeterol and formoterol being long-acting bronchodilators.